@article{3004335,
    title = "The CONSORT statement checklist in allergen-specific immunotherapy: A GA 2LEN paper",
    author = "Bousquet, P.J. and Brozek, J. and Bachert, C. and Bieber, T. and Bonini, S. and Burney, P. and Calderon, M. and Canonica, G.W. and Compalati, E. and Daures, J.P. and Delgado, L. and Demoly, P. and Dahl, R. and Durham, S.R. and Kowalski, M.L. and Malling, H.J. and Merk, H. and Papadopoulos, N. and Passalacqua, G. and Simon, H.U. and Worms, M. and Wahn, U. and Zuberbier, T. and Schünemann, H.J. and Bousquet, J.",
    journal = "Allergy: European Journal of Allergy and Clinical Immunology",
    year = "2009",
    volume = "64",
    number = "12",
    pages = "1737-1745",
    doi = "10.1111/j.1398-9995.2009.02232.x",
    keywords = "allergen;  immunoglobulin E;  placebo;  vaccine, article;  clinical assessment;  clinical research;  health care personnel;  human;  immunotherapy;  methodology;  outcome assessment;  priority journal;  skin test;  treatment withdrawal, Allergens;  Double-Blind Method;  Humans;  Immunotherapy;  Patient Selection;  Randomized Controlled Trials as Topic;  Reference Standards",
    abstract = "The methodology of randomized clinical trials is essential for the critical assessment and registration of therapeutic interventions. The CONSORT (Consolidated Standards of Reporting Trials) statement was developed to alleviate the problems arising from the inadequate reporting of randomized controlled trials. The present article reflects on the items that we believe should be included in the CONSORT checklist in the context of conducting and reporting trials in allergen-specific immunotherapy. Only randomized, blinded (in particular blinding of patients, health care providers, and outcome assessors), placebo-controlled Phase III studies in this article. Our analysis focuses on the definition of patients' inclusion and exclusion criteria, allergen standardization, primary, secondary and exploratory outcomes, reporting of adverse events and analysis. © 2009 John Wiley & Sons A/S."
}